![](https://orbitdiscovery.com/wp-content/uploads/2021/06/orbit-logo-sq-e1662724461974.jpg)
Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new treatment options for a wider range of diseases MARTINSRIED, GERMANY, and OXFORD, UK, 28 May 2024 – Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a […]